Fujifilm (OTCMKTS:FUJIY) Stock Crosses Above 200 Day Moving Average - Time to Sell?

Key Points

• Fujifilm's stock price recently crossed above its two hundred day moving average of $10.93, reaching a high of $12.75 during trading.
• The company's most recent earnings report showed earnings per share (EPS) of $0.15, matching analyst expectations, with a revenue of $5.08 billion.
• Fujifilm has a market capitalization of $30.90 billion and a relatively low debt-to-equity ratio of 0.17, indicating a stable financial position.

Fujifilm Holdings Corp. (OTCMKTS:FUJIY - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $10.93 and traded as high as $12.75. Fujifilm shares last traded at $12.42, with a volume of 117,165 shares changing hands.

Fujifilm Trading Up 0.7%

The company has a market capitalization of $30.90 billion, a PE ratio of 11.19, a price-to-earnings-growth ratio of 2.37 and a beta of 0.70. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.48 and a quick ratio of 0.92. The company's fifty day moving average is $11.91 and its 200-day moving average is $10.93.

Fujifilm (OTCMKTS:FUJIY - Get Free Report) last announced its earnings results on Wednesday, August 6th. The technology company reported $0.15 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.15. Fujifilm had a return on equity of 7.60% and a net margin of 7.93%.The business had revenue of $5.08 billion for the quarter, compared to analysts' expectations of $760.41 billion. On average, analysts anticipate that Fujifilm Holdings Corp. will post 0.66 EPS for the current fiscal year.

Fujifilm Company Profile

FUJIFILM Holdings Corporation develops, manufactures, sells, and services imaging, healthcare, materials, and business innovation solutions worldwide. The company's Healthcare segment provides products and services, such as medical devices, biomedical contract development and manufacturing organization, pharmaceutical, regenerative medicine, and cosmetics and supplements in the areas of prevention, diagnosis, and treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.